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Abstract
Background: Neoadjuvant chemotherapy is the standard care for locally advanced breast cancer. Our study aimed
at evaluating the feasibility of breast conversation surgery (BCS) after neoadjuvant chemotherapy.
Patients and methods: Forty five patients had stage IIB (except those with T2N1 disease) and stage IIIA were
selected to 3 cycles taxane-based neoadjuvant chemotherapy. Patient who had tumours ≤5 cm underwent a
tentative BCS while patients who had tumour size >5 cm underwent radical surgery. Negative margin is essential
for BCS. Adjuvant chemotherapy and 3-D radiotherapy ± hormonal treatment were given to all patients.
Results: Thirty four patients had BCS. Response to chemotherapy was the only statistically significant factor which
influences the BCS. Incidence of local recurrence was 5.9% for patients who had BCS at a median follow up
24 months.
Conclusion: Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast. We
recommend that patients who have tumour size ≤4 cm after chemotherapy are the best candidates for BCS.
Introduction
Long-term survival is common among women with
locally advanced breast cancer; therefore, quality of life
issues become vitally important. For most women, loss
of a breast is emotionally disturbing [1].
The patient’s response to preoperative chemotherapy
is a powerful prognostic factor in predicting disease-free
and overall survival from locally advanced breast cancer
[2,3]. By assessing the response to preoperative che-
motherapy, it is possible to select out a better prognosis
group of patients who will have improved long-term
survival and a low rate of local recurrence. Therefore,
patients who respond to preoperative chemotherapy are
often the best candidates for breast conservation, allow-
ing for less disfigurement with preservation of function
[3,4].
Several studies have documented the feasibility and
safety of breast conservation for locally advanced breast
cancer after preoperative chemotherapy. Breast conser-
vation is possible in 27% to 90% of patients after preo-
perative chemotherapy [4,5]. Local recurrence rates after
breast conservation are low (5% - 10%) in patients who
respond to preoperative chemotherapy [6,7].
Our primary outcome was the evaluation of the feasi-
bility of breast conservation after neoadjuvant che-
motherapy in patients with locally advanced, non
metastatic breast cancer. Secondary outcomes were
assessment of factors which might affect the feasibility
of BCS and the status of surgical margins after breast
conservation and determination of pattern of loco-regio-
nal recurrence, and common toxicity criteria among all
patients after neoadjuvant chemotherapy.
Patients and methods
This prospective phase I study was conducted at South
Egypt Cancer Institute and Sohag cancer centre, Egypt,
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Each case was reviewed in the weekly interdisplinary
tumour board before study inclusion, and all cases gave
written informed consent. This study was approved by
Assiut Faculty of Medicine Institutional Review Board
that gives approval to both South Egypt Cancer Institute
and Sohag Cancer Centre.
(I) Eligibility criteria
A- At presentation: Female patients with biopsy proven
locally advanced, non metastatic breast cancer {Stage IIB
(limited to T3N0) and IIIA disease} and an Eastern
Cooperative Oncology Group performance score of 0 to
1 with exclusion of multicentricity, diffuse microcalcifi-
cation, central and retroareolar tumours, pregnancy and
left ventricular ejection fraction (LVEF) of < 60%.
B- After neoadjuvant chemotherapy: Patients with
tumours ≤5 cm in greatest dimension measured by clini-
cal examination and both breast sonography and
mammography.
Tumour: breast size ratio small enough for a good
cosmetic result (subjective assessment) and no skin
involvement.
C-After breast conservation: Patients with negative
surgical margins.
(II) Pre-treatment evaluation
Each patient was subjected to clinical examination,
laboratory investigations (including complete blood pic-
ture, liver and renal function tests), echocardiography
and breast sono-mammography. Axillary staging was
done clinically and with ultrasound. True-cut needle
biopsy was taken from breast tumor itself for histo-
pathological diagnosis. Metastasis work up was done,
such as chest x- ray, abdomino-pelvic ultrasonography
and bone scan.
(III) Neoadjuvant chemotherapy
Each patient was given 3 cycles of taxene based combi-
nation chemotherapy with 3 weeks interval, (Paclitaxel
135 mg/m
2, Adriamycin 50 mg/m
2 and Cyclophospha-
mide 500 mg/m
2). Three weeks after the third cycle,
each patient was evaluated by clinical examination and
breast sono-mammography to assess the response to
neoadjuvant chemotherapy. Axillary disease was evalu-
ated by physical examination and by ultrasound. Chest
x- ray and abdomino-pelvic ultrasound were done to
exclude patients with distant metastasis.
(IV) Treatment categorization
Patients with tumours ≤5 cm in greatest dimension
underwent conservative breast surgery (wide local exci-
sion with 2 cm safety margin and axillary dissection).
Patients with breast tumours > 5 cm in greatest
dimension or those with persistent positive surgical
margins were excluded from the study and were sub-
jected to modified radical mastectomy (MRM).
(V) Postoperative adjuvant therapy
Each patient in both groups was given additional 3
cycles of taxene based combination chemotherapy fol-
lowed by radiotherapy (RT) of 50 Gy with 2 Gy daily
fractions to breast and chest wall using 3-D planning by
2 parallel opposed tangential fields using 6 MV photon
beams. Supra-clavicular irradiation (50 Gy/25 fractions/5
weeks) was given only to patients with positive axillary
lymph nodes. A boost dose of 16 Gy in 8 fractions to
tumour site using 12 Mev electrons was given to
patients who underwent conservative surgery.
Adjuvant hormonal therapy (tamoxifen, 20 mg/day, in
2 divided doses) was given only to patients with positive
hormonal receptors.
Patients had multiple CT cuts at 1 cm interval
throughout the treatment volume. At each CT slice, the
target volume, heart, ipsilateral and contralateral lungs
were defined. The dose volume histogram for the target
volume and critical organs were obtained for treatment
plan evaluation. The treatment plan was acceptable if
≤10% of the heart volume and ≤25% of the ipsilateral
lung volume received 25 Gy [8].
(VI) Follow up
All patients in this study (in both groups) were followed
up monthly by clinical examination and every 3 months
by sono-mammography to diseased and healthy breasts,
as well as by chest x- ray and abdomino-pelvic ultra-
sound. Treatment related complications were measured
using WHO common toxicity criteria [9].
Statistical methods
Data was analyzed using SPSS version 17. Data was pre-
sented as frequencies and percentages (categorical data)
and as mean ± SD (quantitative data). Statistical analysis
was done using Chi square test (categorical data) and
Wilcoxon signed-rank test (quantitative data). P < 0.05
was considered significant.
Results
The majority of our patients (27 out of 45 patients;
60%) were < 50 years of age , 22 of them were eligible
for BCS. The patients’ age ranged from 35 to 69 years
with the median age of 48 years. Forty one patients
(91%) had large tumour size (> 5 cm); none of them
were fixed to pectoralis major muscle nor to chest
wall; 10 patients of them had no palpable ipsilateral
axillary nodes (T3N0), 25 patients had mobile ipsilat-
eral axillary nodes (T3N1) and only 6 patients had
fixed nodes; table 1.
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neoadjuvant chemotherapy, 36 out of 45 patients had
partial response (80%) with lesions ≤5c ma n du n d e r -
went BCS, 29 patients of them (80.6%) showed negative
(negative) surgical margins and the other 7 patients had
positive margins. With re-resection, five out of the
7 patients had negative margins and the remaining
2 patients had persistent positive surgical margins.
These 2 patients as well as the 9 patients with stable
disease after neoadjuvant chemotherapy underwent
MRM. Thus only 34 out 45 patients (75.6%) underwent
BCS with negative surgical margins. Out of 10 patients
(T3N0) with clinically impalpable and sonographically
non detectable axillary nodal disease, 5 patients (50%)
showed pathologically positive nodal disease after
neoadjuvant chemotherapy and axillary dissection. Fif-
teen out of 35 patients (42.9%) with clinically documen-
ted axillary nodal disease (25 patients with T3N1, 6 with
T3N2 and 4 with T2N2) showed complete clinical nodal
response. All these 15 patients had stage T3N1 disease.
Patients with clinically fixed axillary nodes (10 patients;
6o fT 3 N 2a n d4o fT 2 N 2d i s e a s e )s h o w e do n l yp a r t i a l
response.
The relation of clinical staging with grade and hormo-
nal (HR) status had been studied after neoadjuvant che-
motherapy; table 2. Staging, grade, and HR status were
not statistically significant (> 0.05) on the feasibility of
BCS. On comparison of pre-chemotherapy and post
chemotherapy tumour sizes, there was statistically signif-
icant decrease of tumour size after neoadjuvant
chemotherapy; table 3.
Table 1 Patients’ characteristics
Baseline characteristics of all patients (n = 45) Patients who were eligible for BCS (n = 36)
N%N %
Age at diagnosis
< 50 27 60 22 61.1
≥50 18 40 14 38.9
Tumour size
≤5 cm 4 8.9 4 11.1
> 5 cm 41 91.1 32 88.9
Tumour site
Upper outer quadrant 32 71.1 26 72.2
Lower outer quadrant 9 20 7 19.4
Upper inner quadrant 4 8.9 3 8.3
Laterality
Right sided 24 53.3 19 52.8
Left sided 21 46.7 17 47.2
Clinical staging
T3N0 10 22.2 8 22.2
T3N1 25 55.6 20 55.6
T3N2 6 13.3 4 11.1
T2N2 4 8.9 4 11.1
Histologic grade
Grade II 30 66.7 25 69.4
Grade III 15 33.3 11 30.6
Hormonal status (HR)
HR positive 37 82.2 30 83.3
HR negative 8 17.8 6 16.7
Total 45 100 36 100
Figure 1 The profile of the study.
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tive margins (19.4%) and 29 patients had negative mar-
gins as distributed in table 4. The feasibility of BCS with
negative margins was statistically insignificant as regard
of the stage, grade, and HR status. All patients with post
chemotherapy tumour size <4 cm underwent BCS with
negative surgical margins whereas only 46.2% of those
(6 out of 13 patients) with post chemotherapy tumour
size between 4 and 5 cm showed negative margins.
Therefore, post chemotherapy tumour size was the only
statistically significant factor (P < 0.001) affecting the
feasibility of BCS with negative margins.
The median follow up period was 24 months (range;
21-30 months). There were 2 patients who underwent
BCS developed local recurrence (LR) (5.9%) at the
tumour bed. One of the two patients had also simulta-
neous liver metastases (Distant metastasis rate of 2.9%)
at 18 months. This patient was treated by salvage che-
motherapy (Navelbine/5-flurouracil regimen). The other
patient had only isolated LR at 20 months. This patient
was treated by salvage MRM. The patient who had iso-
lated LR was T3N1M0 disease at presentation with
grade III and HR negative breast cancer. The other
patients who had total disease relapse (LR and DM)
were T3N2M0 disease at presentation with grade III
and HR negative tumour. There was only one patient
who underwent MRM (one out of 11 patients; 9.1%)
developed LR at operative scar and this recurrent
nodule was surgically excised. Distant metastasis did not
occur in mastectomized patients.
The most common toxicity criteria following neoadju-
vant chemotherapy among our patients was fatigue
(40 patients; 88.9%) followed by grade 2 alopecia
(38 patients; 84.4%). Athralgia and myalgia were devel-
oped in 8 patients (17.8%) whereas febrile neutropenia
occurred in only 3 patients (6.7%); table 5. All patients
completed the treatment protocol without interruption
of treatment. There were no RT pneumonitis, and no
severe cardiac toxicity occurred among the patients
accrued to this study. The only radiation induced skin
toxicity encountered was dry desquamation which did
not necessitate interruption of radiation therapy.
Discussion
This study emphasizes two important points: first, the
high feasibility of BCS after neoadjuvant chemotherapy,
and second, the good tolerability of patients to treat-
ment with low incidence of grade 3 and grade 4 toxicity.
In the present study, after neoadjuvant chemotherapy,
36 out of 45 patients showed partial response with post
chemotherapy tumour size ≤5c m .T h i sf i g u r eo f
response is within the range of the reported studies
where Newman et al. [10] found that 75% of patients
were feasible to BCS. The overall objective response of
the primary tumour in patients with locally advanced
breast cancer ranged from 71% to 87% [11,12]. On the
other hand, our results are much higher than that
reported by Yadav et al. [13] who found that only 23%
of patients with locally advanced breast cancer were
candidates for BCS after neoadjuvant chemotherapy.
This difference could be explained on the ground that
the reported study used anthracycline based chemother-
apy (FAC regimen) while in the current study we used
taxene based chemotherapy (TAC regimen).
The vast majority of our patients (41 patients, 91%)
had large tumour size (> 5 cm), 10 patients of them
(22.2%) had T3N0 (stage IIB), 25 patients (55.6%) had
T3N1 (stage IIIA) and only 6 patients (13.3%) had fixed
nodes (stage IIIA). Our figures are different than those
reported by Formenti et al. [14] where 36% patients had
stage IIB (T3N0) tumours, 30% had stage IIIA, and 34%
had stage IIIB. This may be due to exclusion of stage
IIIB cases in our study.
The mean prechemotherapy tumour size was 6.4 ± 1.4
cm in the present study which was similar to that
reported by Chen et al. [15] where the median tumour
size before chemotherapy was 6.0 cm. Our figure is also
comparable with that reported by Viswambharan et al.
[12] where the size of the primary tumour ranged from
5-9 cm (mean = 7.1 cm). The mean post-chemotherapy
tumour size in our study, was 3.9 ± 1.3 cm which was
comparable to figures reported by Chen et al. [15] (2.2
to 3.2 cm) and Viswambharan et al. [12] (3.8 cm).
In the current study, we found that stage, grade, and
HR were not statistically significant on the response to
chemotherapy. However, the reported series showed
that nuclear grade[16] and HR negative status[17,18]
Table 2 Relation of Clinical staging with grade and
hormonal (HR) status showing feasibility of BCS after
neoadjuvant chemotherapy
Clinical Stage N Grade HR
G II G III HR + HR -
T3N0 10 (8) 8 (6) 2 (2) 9 (8) 1 (0)
T3N1 25 (20) 16 (12) 9 (8) 22 (17) 3 (3)
T3N2 6 (4) 4 (2) 2 (2) 3 (1) 3 (3)
T2N2 4 (4) 2 (2) 2 (2) 3 (3) 1 (1)
Total 45 (36) 30 (22) 15 (14) 37 (29) 8 (7)
N.B.: Numbers between brackets refer to numbers of patients whose post
chemotherapy tumour size ≤5 cm and were candidates for BCS in different
stage groups according to grade and HR status.
Table 3 Comparison of pre-chemotherapy tumour size
and post chemotherapy tumour size
Pre-chemotherapy tumour
size
Post-chemotherapy tumour
size
P
value*
6.4 ± 1.4 cm 3.9 ± 1.3 cm < 0.001
* Wilcoxon signed-rank test
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perative chemotherapy. This difference may be
explained by the larger number of patients in the
reported series (287 patients in Abu-Farsakh et al. [16],
60 patients in Sarid et al. [17], and 399 patients in Col-
lini et al. [18]). All patients with post chemotherapy
tumour size <4 cm underwent BCS with negative surgi-
cal margins whereas only 46.2% of those (6 out of 13
patients) with post chemotherapy tumour size between
4 and 5 cm were feasible for BCS with negative margins.
This is in agreement with Neuman et al. [10] who stated
that post-chemotherapy tumour size less than 4 cm is a
favourable criterion regarding the feasibility of BCS.
The rate of positive margins, in our study, was 19.4% (7
out of 36 patients) which was higher than that observed
by Mittra et al. [19] where only 2.4% of patients with BCS
showed positive margins. This difference may be
explained by the larger number of patients in their study
(726 patients) than in our study (36 patients).
All patients with post chemotherapy tumour size <4
cm underwent BCS with negative surgical margins
whereas only 46.2% of those (6 out of 13 patients) with
post chemotherapy tumour size between 4 and 5 cm
showed negative margins. After re-resection most of
patients with positive margins (5 out of 7 patients;
71.4%) achieved negative margins, but with compro-
mised cosmetic appearance. This can be explained on
t h eg r o u n dt h a t ,t h e r ew a sas i g n i f i c a n ta s s o c i a t i o n
between pre-chemotherapy tumour size and
histopathological margin status. There was also, a signif-
icant association between post-chemotherapy tumour
size and histopathological margin status[12]. In patients
with post-chemotherapy tumour size >4 cm, 10/13
(77%) were margin positive and 3/13 (23%) were margin
negative whereas in patients with post-chemotherapy
size >3 cm, 13/24 (54%) were margin positive and 11/24
(46%) were margin negative. In patients with post-che-
m o t h e r a p ys i z e< 3c m ,1 / 6( 1 7 % )w e r em a r g i np o s i t i v e
and 5/6 (83%) were margin negative. Therefore a smaller
post-chemotherapy size is found to give lesser margin
positivity and better cosmetic appearance. Therefore the
recommendation for breast conservation surgery was for
tumours up to 4 cm[20].
In this study, the median follow up time from the date
of registration in outpatient clinic was 24 months (range
21-30 months). The relapse rate among patients who
underwent conservative surgery was 5.9% (2 out of 34
patients). This figure is identical to that reported by
Mittra et al. [19] who found a 5.9% relapse rate among
patients in the conservative surgery group. Another
study from the M. D. Anderson Cancer Centre evalu-
ated outcome after induction chemotherapy and BCT
for 93 patients with locally advanced or large primary
breast cancers and found a local recurrence rate of
<10%. This was comparable to the local recurrence rate
seen in patients with early-stage breast cancer treated
with a breast-conserving approach[21].
It is reassuring to note that the tolerance to preopera-
tive chemotherapy was very good. Adverse effects were
mostly of grade 1 or 2 severities. Grade 4 leucopenia
was observed in only 3 cases. The most common toxi-
city criteria following neoadjuvant chemotherapy among
o u rp a t i e n t sw a sf a t i g u e( 8 8 . 9 % ) .T h i si sm a t c h e dw i t h
Sarid et al. [17] who found that adverse effects were
mostly of grade 1 or 2 and the most common side effect
was fatigue. Alopecia was observed in 84.4% of cases.
This is comparable with Formenti et al. [14] who
observed a 92.7% rate of alopecia in their study (38 of
41 patients). Athralgia and myalgia developed in 17.8%,
diarrhoea in 11.1% and mouth sore in 8.9%. Febrile
Table 4 Relation between clinical staging with grade, hormonal (HR) status and post chemotherapy tumour size
showing status of surgical margin in patient who did BCS
Clinical Stage N Grade HR status Post-chemotherapy tumour size
G II G III HR + HR - < 4 cm 4-5 cm
T3N0 8 (6) 6 (5) 2 (1) 8 (6) 0 (0) 5 (5) 3 (1)
T3N1 20 (17) 12 (10) 8 (7) 17 (15) 3 (2) 12 (12) 8 (5)
T3N2 4 (2) 2 (0) 2 (2) 1 (0) 3 (2) 2 (2) 2 (0)
T2N2 4 (4) 2 (2) 2 (2) 3 (3) 1 (1) 4 (4) 0 (0)
Total 36 (29) 22 (17) 14 (12) 29 (23) 7 (6) 23 (23) 13 (6)
N.B.: Numbers between brackets refer to numbers of patients who did BCS with free surgical margins in different stage groups according to grade, HR status and
post chemotherapy tumour size.
Table 5 Common toxicity criteria among all patients after
neoadjuvant chemotherapy
Variable Chemotherapy toxicity
N%
Fatigue 40 88.9
Alopecia 38 84.4
Arthralgia and myalgia 8 17.8
Diarrhoea 5 11.1
Mouth sores 4 8.9
Febrile neutropenia 3 6.7
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occurred in only 6.7% of patients. Formenti et al. [14]
found similar results where arthralgia was observed in
17%, stomatitis in 12%, and febrile neutropenia in 9.7%
of patients. On the other hand, Chen et al. [15] found a
lower incidence of febrile neutropenia (2%) which may
be due to their use the regimen of weekly taxol which is
more tolerable with fewer side effects.
It is interesting that no RT pneumonitis occurred
among the patients accrued to this study. There was
also no severe cardiac toxicity. The finding is consistent
with the University of Washington’s experience and is in
contrast with that reported by Yu et al. [22] who
observed RT pneumonitis in 19% of 21 breast cancer
patients treated by concurrent paclitaxel and RT and
20% of 16 patients who received RT after paclitaxel.
Both groups of patients, however, were treated post-
operatively and after doxorubicin-based chemotherapy.
It is possible that the sequencing of anthracycline-based
chemotherapy and taxanes affects the pulmonary mor-
bidity of subsequent RT therapy[14]. The absence of
radiation related pulmonary toxicity in our series, may
also be attributed to the use of 3-D radiation therapy
planning for our patients.
Conclusions and recommendations
Breast conservation is feasible in selected cases of locally
advanced, non-metastatic cancer breast, after neoadju-
vant chemotherapy. Response to chemotherapy is the
most important factor to select patients for BCS. We
recommend that patients who have tumour size ≤4c m
after chemotherapy are the best candidates for BCS.
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